Semi-automated pharmacoepidemiology studies

Semi-automated pharmacoepidemiology studies Reactions 1664, p12 - 12 Aug 2017 Semi-automated pharmacoepidemiology studies Signals of medicine-related adverse events can be generated using semi-automated pharmacoepidemiology studies, according to results reported in Drug Safety, and "provides an opportunity for the rapid assessment of risk in post-marketing surveillance of medicine safety". Three national databases in New Zealand recording practice registers, hospital discharges and medicine use data were linked to include 5194 256 patients in 2007–2014, a total of 34 630 673 patient-years at risk. Using a newly developed semi-automated computer system, retrospective nested case-control designs evaluated risk for known drug class-adverse event pairs. Cases included patients with a hospital diagnosis recorded for the relevant study outcome. The 8274 cases hospitalised with upper gastrointestinal bleeding were matched with 41 365 controls. NSAIDs had been used by 26.1% of cases in the 3 months prior to hospitalisation, compared with 7.9% of controls (adjusted odds ratio [OR] 4.16; 95% CI 3.90, 4.43; p<0.001). SSRIs had been used by 8.5% of cases and 6.5% of controls (OR 1.39; 1.20, 1.62; p<0.001). Similarly, there was a significantly increased bleeding risk for patients who had received antiplatelets (OR 1.70), warfarin (OR 1.96) or dabigatran etexilate (OR 1.57). The 73 471 patients hospitalised with acute kidney failure (AKF) were compared with 348 075 controls. NSAIDs had been used by 13.6% of cases in the 3 months prior to hospitalisation, compared with 7.4% of controls (OR 1.78; 1.73, 1.83). Proton pump inhibitors had been used by 37.4% of cases and 20.3% of controls (OR 1.78; 1.72, 1.83; p<0.001). Similarly, there was a significantly increased AKF risk for patients who had received H2 antagonists (OR 1.65), diuretics (OR 1.95), ACE/A-II inhibitors (OR 2.00), or antibiotics (OR 2.27). The 17 323 patients with serious arrhythmia were compared with 86 549 controls. Antibiotics had been used by 32.7% of cases and 18.2% of controls (OR 1.72; 1.65, 1.79; p<0.001). There was a high risk for patients receiving fluoroquinolones (OR 1.38) or penicillins (OR 1.69). There was also a high risk for patients receiving antidepressants (OR 1.46) or anti-nausea and anti-vertigo agents (OR 1.30), and for antipsychotics prescribed within the previous 7 days (OR 1.27). Risks were generally higher among new medicine users, and when concomitant high-risk medicines were used. The estimates of risk were "consistent with findings from epidemiological studies conducted previously," note the authors. Study results were able to be generated within one day, although the authors note that "medical and pharmacological expertise and assessment is required in the interpretation of the results generated". The ability to analyse risks due to multiple drug therapy "could potentially inform prescribers of increased risk for their patients when prescribing additional medicines," note the authors. Tomlin AM, et al. A Pharmacoepidemiology Database System for Monitoring Risk Due to the Use of Medicines by New Zealand Primary Care Patients. Drug Safety : 1 Aug 2017. Available from: URL: http://dx.doi.org/10.1007/ s40264-017-0579-1 803263635 0114-9954/17/1664-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 12 Aug 2017 No. 1664 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Semi-automated pharmacoepidemiology studies

Reactions Weekly , Volume 1664 (1) – Aug 12, 2017
Free
1 page

Loading next page...
1 Page
 
/lp/springer_journal/semi-automated-pharmacoepidemiology-studies-1kJePvpAQx
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-34292-0
Publisher site
See Article on Publisher Site

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial